Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 6/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12228594 | 0.81 | TSHR (0.36) | TSHRCYP3A4TP53ALDH1A1MAPK1 | |
| SCHEMBL17649942 | 0.77 | TSHR (0.40) | TSHRCYP3A4TP53ALDH1A1MAPK1 | |
| SCHEMBL27540955 | 0.75 | TSHR (0.39) | TSHRCYP3A4TP53ALDH1A1MAPK1 | |
| SCHEMBL3870951 | 0.75 | TSHR (0.39) | TSHRCYP3A4TP53ALDH1A1MAPK1 | |
| SCHEMBL30216043 | 0.75 | ALDH1A1 (0.39) | ALDH1A1CA12CA1CA2CA7 | |
| SCHEMBL14964653 | 0.75 | ALDH1A1 (0.39) | ALDH1A1CA12CA1CA2CA7 | |
| SCHEMBL159338 | 0.75 | TSHR (0.39) | TSHRCYP3A4TP53ALDH1A1MAPK1 | |
| SCHEMBL29435968 | 0.75 | TSHR (0.39) | TSHRCYP3A4TP53ALDH1A1MAPK1 | |
| SCHEMBL18935880 | 0.73 | NOTUM (0.40) | TSHRCYP3A4ALDH1A1MAPK1CA12 | |
| SCHEMBL7460667 | 0.71 | CA1 (0.43) | TSHRCYP3A4TP53ALDH1A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3498693-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2024-10-30 | — | — | EP | disclosed |
| WO-2022266458-A1 | 6-HETEROCYCLOALKYL-QUINAZOLINE DERIVATIVES AND USES THEREOF | BLACK DIAMOND THERAPEUTICS, INC. (US) | 2022-12-22 | — | — | WO | disclosed |
| CN-109790122-B | Heterocyclic compounds | 武田药品工业株式会社 | 2022-06-24 | — | — | CN | disclosed |
| US-10696651-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-06-30 | — | — | US | disclosed |
| EP-3498693-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2019-06-19 | — | — | EP | disclosed |
| US-20190169166-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-06-06 | — | — | US | disclosed |
| US-20140058129-A1 | Phenylacetic Acid Derivatives | NOVARTIS AG (CH) | 2014-02-27 | — | — | US | disclosed |
| US-8586782-B2 | Phenylacetic acid derivatives | NOVARTIS AG (CH) | 2013-11-19 | — | — | US | disclosed |
| US-8362294-B2 | Phenylacetic acid derivatives | NOVARTIS AG (CH) | 2013-01-29 | — | — | US | disclosed |
| US-20130012585-A1 | Phenylacetic Acid Derivatives | MONOVICH LAUREN G (US) | 2013-01-10 | — | — | US | disclosed |
| EP-2046723-B1 | PHENYLACETIC ACID DERIVATIVES AS COX-2 INHIBITORS | NOVARTIS AG (CH) | 2012-07-18 | — | — | EP | disclosed |
| US-20090209648-A1 | Phenylacetic Acid Derivatives | NOVARTIS AG (CH) | 2009-08-20 | — | — | US | disclosed |
| CN-101479231-A | Phenylacetic acid derivatives as COX-2 inhibitors | NOVARTIS AG (CH) | 2009-07-08 | — | — | CN | disclosed |
| EP-2046723-A2 | PHENYLACETIC ACID DERIVATIVES AS COX-2 INHIBITORS | Novartis AG (CH) | 2009-04-15 | — | — | EP | disclosed |
| WO-2008002853-A2 | PHENYLACETIC ACID DERIVATIVES AS COX-2 INHIBITORS | NOVARTIS AG (CH) | 2008-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140058129-A1 | Phenylacetic Acid Derivatives | PTGES2, PTGS2, GOT2 | TSHR 2476/4885CYP3A4 86/4885TP53 2901/4885 |
| US-10696651-B2 | Heterocyclic compound | EIF2AK4, GCN1, GTF2I | TSHR 4596/4885CYP3A4 4156/4885TP53 1502/4885 |
| US-20190169166-A1 | HETEROCYCLIC COMPOUND | EIF2AK4, GCN1, GTF2I | TSHR 4596/4885CYP3A4 4156/4885TP53 1502/4885 |
| US-20130012585-A1 | Phenylacetic Acid Derivatives | PTGES2, PTGS2, GOT2 | TSHR 2476/4885CYP3A4 86/4885TP53 2901/4885 |
| US-20090209648-A1 | Phenylacetic Acid Derivatives | PTGES2, PTGS2, PTGER2 | TSHR 2586/4885CYP3A4 82/4885TP53 2891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.